Novartis seeks dismissal of Gleevec pay-for-delay case
MLex Summary: Novartis filed a motion to dismiss claims that it unlawfully delayed the market entry of generic versions of the chronic myeloid leukemia drug Gleevec. Novartis says plaintiffs’ allegations that...To view the full article, register now.
Already a subscriber? Click here to view full article